TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ewing's family of tumors~* Current disease state for which there is no curative therapy~Exclusion Criteria:~* Prior anti-IGF-1R therapy~* Concurrent treatment with other anti-cancer agents

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Calcium Retention as Influenced by Dietary Components That Induce an Acid Load

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Average body mass index~* Normal blood work~* Normal bone density~Exclusion Criteria:~* Chronic disorder~* Non-traumatic bone fractures

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): Dietary Intervention: High meat and high acid load diet followed by low meat and low acid load diet
- B (Type: EXPERIMENTAL): Dietary Intervention: Low meat and low acid load diet followed by high meat and high acid load diet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* At least 12 years of age.~* Body weight at least 40 kg (approximately 88 pounds).~* Pulmonary hypertension (PAH) that is either idiopathic; related to collagen vascular disease; related to anorexigen use; associated with an atrial septal defect (resting SaO2 greater than or equal to 88%); with surgical repair, of at least 1 year duration, of a congenital systemic-to-pulmonary shunt.~* If on bosentan, must be at the maximal dose of 125 mg twice daily for a minimum of 12 weeks prior to screening and have an AST/ALT less than 3 times normal.~* History of PAH established by a resting mean pulmonary artery pressure greater than or equal to 25 mm Hg, pulmonary artery wedge pressure less than or equal to 15 mm Hg, and pulmonary vascular resistance greater than or equal to 3 Wood units via right heart catheterization~* Have World Health Organization functional class I, II, III or IV status.~* Have a qualifying 6-minute walk test distance at screening~* Have no evidence of significant parenchymal lung disease~Exclusion Criteria:~* Are nursing or pregnant.~* PAH due to conditions other than noted in the above inclusion criteria.~* History of left-sided heart disease.~* History of atrial septostomy within 3 months before study entry~* History of angina pectoris or other condition that was treated with long-or short-acting nitrates within 12 weeks before administration of study drug.~* History of symptomatic coronary disease.~* Have any therapy with a prostacyclin or analogue, L-arginine, phosphodiesterase (PDE) inhibitor, or investigational drug within 4 weeks before administration of study drug.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: ACTIVE_COMPARATOR): 2.5 mg tadalafil
- 3 (Type: ACTIVE_COMPARATOR): 10 mg tadalafil
- 4 (Type: ACTIVE_COMPARATOR): 20 mg tadalafil
- 5 (Type: ACTIVE_COMPARATOR): 40 mg tadalafil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Healthy adult males age 18 - 50 years, BMI 19-32 kg/m2~* Acceptable duration of cold pain test results at screening~Exclusion Criteria:~* Clinically significant medical illness or physical exam findings~* Active dermatological conditions or skin trauma on the non-dominant hand, or peripheral vascular disease~* Partial blindness, keratoconus, nystagmus or any other ophthalmic condition which could interfere with pupillometry~* Use of tobacco or nicotine within 6 months prior to screening~* History of recent (within 6 months) drug or alcohol abuse, as defined in DSM-IV-TR

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- TRV130 1.5 mg (Type: EXPERIMENTAL): TRV130 1.5 mg IV x 1 dose
- TRV130 3 mg (Type: EXPERIMENTAL): TRV130 3 mg IV x 1 dose
- TRV130 4.5 mg (Type: EXPERIMENTAL): TRV130 4.5 mg IV x 1 dose
- Morphine (Type: ACTIVE_COMPARATOR): Morphine 10 mg IV x 1 dose
- Placebo (Type: PLACEBO_COMPARATOR): Dextrose 5% in water IV x 1 dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Artemisia Dracunculus on Glucose Intolerance, Insulin Sensitivity and Insulin Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients both sexes~* Age between 30 and 60 years~* Glucose intolerance according ADA criteria (blood glucose leve ≥140 mg/dl and ≤199 mg/dL after an oral glucose tolerance test with 75 of oral glucose~* Informed consent signed~Exclusion Criteria:~* Women with confirmed or suspected pregnancy~* Women under lactation and/or puerperium~* Hypersensibility to Artemisia dracunculus~* Physical impossibility for taking pills~* Known uncontrolled renal, hepatic, heart or thyroid disease~* Previous treatment for glucose~* Diabetes diagnosis~* BMI ≥39.9 kg/m2

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Artemisia Dracunculus (Type: EXPERIMENTAL): Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
- Placebo (Type: PLACEBO_COMPARATOR): Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* males and females, 18 to 50 years of age~* non-smoking or light-smoking (≤5 cigarettes per day) volunteers~* BMI ≥ 40 kg/m2~* female subjects of childbearing potential either surgically sterilized, using an effective method of contraception (diaphragm, cervical cap,condom) or agree to abstain from sex from time of pre-study screening, during entire study period and 1 week following the study period.~Exclusion Criteria:~* history of significant hypersensitivity reaction to oseltamivir~* history of gastric bypass surgical procedure~* history of significant clinical illness requiring pharmacological management~* abnormal serum electrolyte or complete blood count requiring further clinical work-up~* transaminases (AST or ALT) \>2.5 x upper limit of normal~* estimated creatinine clearance \<50 mL/min (Cockcroft-Gault equation)~* positive urine pregnancy test (if female)~* abnormal electrocardiogram (ECG) as judged by study physician~* unable to tolerate venipuncture and multiple blood draws~* clinically significant abnormal physical examination defined as a physical finding requiring further clinical work-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Oseltamivir Dosed Group (Type: EXPERIMENTAL): Oseltamivir 75 mg by mouth every 12 hours for 9 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: INFUSE Morphine Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females at least 18 years of age who are patients of San Diego Hospice \& Palliative Care or recruited through San Diego Hospice \& Palliative Care or the UCSD Center for Pain and Palliative Medicine.~2. During the treatment days of the study, on opioid therapy other than morphine that is equivalent to ≥ 60 mg oral morphine per day and without unacceptable toxicity.~3. Vital signs (BP, HR, RR) within normal range.~4. Adequate venous access in both upper extremities.~5. A negative pregnancy test (if female of child-bearing potential) within 7 days prior to first injection.~6. Life expectancy ≥ ten days.~7. Decision-making capacity.~8. Signed, written IRB-approved informed consent. -~Exclusion Criteria:~1. Known hypersensitivity or history of any toxicity to morphine.~2. Morphine within the 4 days prior to the first study medication injection or anticipated to be receiving morphine during any of the treatment days in this study.~3. Any contraindication to morphine.~4. Known hypersensitivity to naloxone.~5. Known allergy to hyaluronidase or any other ingredient in the formulation of HYLENEX.~6. Known allergy to bee or vespid venom.~7. Contraindication to IV heparin lock or known hypersensitivity to heparin.~8. Edema, infection, or any other lower extremity or pelvic disorder that might affect subcutaneous absorption from the thigh.~9. Hemoglobin \< 10 g/dL.~10. Presence of any other medical condition that would present an unacceptable safety risk to the patient.~11. Participation in a study of any investigational drug or device within 30 days of enrollment in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): IV Morphine
- 2 (Type: EXPERIMENTAL): SC Morphine with Hylenex
- 3 (Type: ACTIVE_COMPARATOR): SC Morphine with Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female and between the ages of 20 and 75 years diagnosed with dyslipidemia~Exclusion Criteria:~* Patients has Coronary Heart Disease (CHD) or CHD-equivalent disease (except diabetes)~* Patients has uncontrolled diabetes~* Patient is currently participating or has participated in a study with an investigational compound within the last 3 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MK0859 10 mg + placebo
- 2 (Type: EXPERIMENTAL): MK0859 40 mg + placebo
- 3 (Type: EXPERIMENTAL): MK0859 100 mg + placebo
- 4 (Type: EXPERIMENTAL): MK0859 300 mg + placebo
- 5 (Type: EXPERIMENTAL): MK0859 10 mg + atorvastatin 10mg
- 6 (Type: EXPERIMENTAL): MK0859 40 mg + atorvastatin 10mg
- 7 (Type: EXPERIMENTAL): MK0859 100 mg + atorvastatin 10mg
- 8 (Type: EXPERIMENTAL): MK0859 300 mg + atorvastatin 10mg
- 9 (Type: PLACEBO_COMPARATOR): Placebo + atorvastatin 10mg
- 10 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Para-cervical Block Prior to Laparoscopic Hysterectomy as an Adjuvant Treatment to Reduce Postoperative Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing laparoscopic hysterectomy with or without salpingoophorectomy for benign indications~* Undergoing laparoscopic hysterectomy with robotic assistance with or without salpingoophorectomy for benign indications~* Between 18 and 60 years of age~Exclusion Criteria:~* Intraoperative detection of malignancy~* Undergoing additional procedures at the time of surgery (except prophylactic McCall culdoplasty/uterosacral ligament suspension, excision of endometriosis, appendectomy, cystoscopy)~* Inability to perform paracervical block due to anatomic abnormalities (absent/flush cervix)~* Known allergy/sensitivity to bupivacaine~* Intraoperative bowel injury, bladder injury, ureter injury or major vessel injury that required repair.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): Injection of 10 mL of 0.9% sodium chloride into the cervical stroma divided between 3 and 9 o'clock
- Study Group (Type: ACTIVE_COMPARATOR): Injection of 10 mL of 0.5% bupivacaine into the cervical stroma divided between 3 and 9 o'clock.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neuropathic Pain After Orchidectomy and Sex Reassignment Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Surgery at least 6 month before data collection~* german speaking~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- ORC (Type: None): Group orchidectomy following cancer
- GAC (Type: None): Group sex reassignment surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* History and subjective symptoms of cat dander allergy including cat specific allergic rhinitis~* Age 18 to 65 years~* Positive reaction to at least one concentration of cat dander allergen in skin prick test, intradermal provocation test and nasal provocation test~Exclusion criteria:~* Chronic infectious disease~* Acute infections~* Episode of non-allergic rhinitis within the last 4 weeks~* Use of allergen known to predict anaphylactic reactions~* Treatment with any other investigational drug within 3 months before trial entry~* Vaccination within the last week~* Nasal surgery within the last 8 weeks~* Progressive fatal disease~* Drug or alcohol abuse within the last 5 years~* Cat ownership~* A history of significant cardiac insufficiency (NYHA stage III-IV)~* Coexisting severe disease, e.g. cardiovascular diseases~* Acute or history of obstructive respiratory insufficiency ( FEV1 \<70%)~* Hepatic insufficiency~* Relevant anaemia (as judged by investigator)~* Blood donation within the last 30 days or intended blood donation (during the study or 30 days after participation)~* Pregnancy or breast feeding~* Sexually active woman of childbearing potential not actively practicing birth control by using a medically accepted device or therapy~* Lack of compliance or other sililar reason, that the investigator believes, precludes satisfactory participation in the study~* Systemic glucocorticoid therapy~* Allergic asthma and chronic medication with steroids at doses exceeding 200ug/day Treatment with ATII antagonists, B-blocker, ACE inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Study drug
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Epidural Magnesium Sulfate for Post-thoracotomy Pain Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists physical statuses I-III~* Undergoing thoracotomy~Exclusion Criteria:~* Known hypersensitivity to magnesium sulfate~* Renal failure~* Hepatic dysfunction~* Severe obesity~* Psychotic or neurologic diseases~* Currently taking opioid or calcium channel blocker~* AV block degree II or III~* Refused to participate in trial

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Group I (Type: ACTIVE_COMPARATOR): magnesium group (Mg)
- Group II (Type: PLACEBO_COMPARATOR): control group (C)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed metastatic breast cancer Bidimensionally measurable disease Hormone receptor status: Not specified~PATIENT CHARACTERISTICS: Age: 18 to 75 Sex: Female Menopausal status: Not specified Performance status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic: ANC at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN) Renal: Creatinine less than 1.5 times ULN Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Eligible patients may have received prior chemotherapy in metastatic or adjuvant setting with the following exceptions: At least 12 months since prior fluoropyrimidine therapy At least 12 months since prior taxane therapy Only 1 previous chemotherapeutic regimen in the metastatic setting Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior radiotherapy Surgery: Not specified

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A DSM-IV diagnosis of schizophrenia (disorganized, catatonic, paranoid, residual, or undifferentiated type) for at least 1 year before the screening evaluation~* a total PANSS score of 70 to 120 at screening and baseline (pre-treatment) evaluations~* a body mass index (BMI \[weight (kilograms)\]/\[height (meters)\]²) of more than 17.0 kg/m²~Exclusion Criteria:~* A primary active DSM-IV Axis I diagnosis other than schizophrenia~* a decrease of 25% or more in the total PANSS score between screening and baseline evaluations~* a DSM-IV diagnosis of active substance dependence within 3 months of screening evaluation~* a history of treatment resistance as defined by failure to respond to 2 adequate trials of different antipsychotic medications~* a woman who is pregnant, breast-feeding, or planning to become pregnant during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete